{"schema_version":"secwatch.filing_event.v1","accession":"0001831283-23-000141","form_type":"8-K","ticker":"LIANY","cik":"0001831283","company_name":"LianBio","filed_at":"2023-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.843178+00:00","generated_at":"2026-06-07T10:02:07.582368+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"LianBio CFO Yi Larson resigns; Ehong Gu named interim CFO","bullets":["Yi Larson resigned as CFO effective December 19, 2023, to pursue other opportunities.","Separation agreement provides severance of $2,430,124 paid in installments and lump sum.","Ehong Gu, VP Head of Global Finance, appointed interim CFO as principal financial officer.","Gu has held senior finance roles at CStone, BeiGene, and Celgene; no compensation terms set yet."],"urls":{"canonical":"https://secwatch.observer/filing/0001831283-23-000141","json":"https://secwatch.observer/filing/0001831283-23-000141.json","markdown":"https://secwatch.observer/filing/0001831283-23-000141.md","text":"https://secwatch.observer/filing/0001831283-23-000141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000141/0001831283-23-000141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000141/lian-20231219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T10:02:07.582368+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2cb94a4ee1","claim":"Ehong Gu was appointed as Interim Chief Financial Officer at LianBio.","evidence_excerpt":"In connection with Ms. Larson’s departure, effective December 19, 2023, the Board appointed Ehong Gu as Interim Chief Financial Officer of the Company, in which role she will act as the Company’s principal financial officer and principal accounting officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000141/0001831283-23-000141-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"e3ab43e9de","claim":"Yi Larson resigned as Chief Financial Officer at LianBio.","evidence_excerpt":"Yi Larson, the Company’s Chief Financial Officer, has decided to resign from the Company, effective December 19, 2023, to pursue other business and professional interests and opportunities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000141/0001831283-23-000141-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}